Published: Wed, February 15, 2017
Economy | By Melissa Porter

Teva Pharma Q4 Profit Beats Estimates; Reaffirms 2017 Non-GAAP Guidance

The company said its bottom line advanced to $1.48 billion, or $1.38 per share. RBC Capital Markets' target price points to a potential upside of 23.53% from the company's current price. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is now 67.44%. Institutional investors own 55.03% of the company's stock.

Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms.

Teva Pharmaceutical Industries ($TEVA) is scheduled to release earnings before Monday's open (Feb 13, 2017). Maxim Group lowered their price objective on shares of Teva Pharmaceutical Industries Limited from $41.00 to $40.00 and set a "hold" rating on the stock in a research report on Monday. Sharkey Howes & Javer now owns 2,008 shares of the company's stock valued at $101,000 after buying an additional 358 shares in the last quarter. Kistler Tiffany Companies LLC now owns 2,437 shares of the company's stock worth $112,000 after buying an additional 302 shares during the last quarter. Mizuho reaffirmed a "neutral" rating and set a $27.00 target price (down from $40.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, February 7th. Teva Pharmaceutical Industries Limited's revenue was up 15.3% compared to the same quarter a year ago. Teva Pharmaceutical Industries Limited's quarterly revenue was up 33.0% compared to the same quarter a year ago. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 14.1% in the third quarter.

Analysts polled by Thomson Reuters had expected earnings of $1.35 a share on $6.28 billion in revenue. The third largest holder is Barrow Hanley Mewhinney & Strauss Llc, which now holds $1.04 billion worth of this stock and that ownership represents almost 3% of its market capitalization.

On a GAAP basis, however, Teva reported a net loss attributable to ordinary shareholders of $1.0 billion, or $1.10 a share, compared to a profit of $500 million, $0.55 a share, in the fourth quarter of 2015. Teva hit a record high of $72.31/share in 2015 and is now trading near $32/share. Fmr Llc owns $2.03 billion in Teva Pharmaceutical Industries Limited, which represents roughly 5.83% of the company's market cap and approximately 10.93% of the institutional ownership. The company has an average rating of "Buy" and a consensus price target of $53.88. Finally, JFS Wealth Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 139.0% in the third quarter.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 0.19% during midday trading on Friday, hitting $32.19. Company price to earnings (P/E) ratio, which measures the relationship between the earnings of a company and its stock price, is calculated as 19.64. Excluding certain items, per-share earnings were $1.38, up from $1.28 a share in the prior-year quarter.

According to FactSet data, TEVA stock has received different ratings from Financial Analysts. If you are reading this news story on another website, it was copied illegally and reposted in violation of global copyright and trademark laws.

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. In its specialty segment, revenue grew 4.2% to $2.2 billion due to higher revenue in other specialty drugs and women's health.

Global sales of Copaxone, the multiple sclerosis treatment that accounts for an outsized proportion of Teva's sales and profits, rose 6% in the quarter to $1 billion - but that was before the patents were ruled invalid.

Like this: